Bausch Health Companies Inc. (BHC) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Bausch Health (BHC) Q2 2026: EBITDA Margin Jumps 530bps as Salix and Solta Drive Outperformance
  July 30, 2026
• Bausch Health (BHC) Q1 2026: Solta China Revenue Soars 193%, Accelerating Global Growth Leverage
  June 16, 2026
• Bausch Health (BHC) Q3 2025: Solta Surges 25% as Strategic Focus Shifts to Innovation and Deleveraging
  June 16, 2026
• Bausch Health (BHC) Q2 2025: Solta Revenue Up 25%, Fueling Margin Expansion and Debt Flexibility
  July 30, 2025
• Bausch Health (BHC) Q1 2025: $7.9B Debt Refinancing Extends Runway, But Tariff and Cash Flow Headwinds Loom
  July 04, 2025
• Bausch Health (BHC) Q3 2024: Operating Cash Flow Jumps 75% as Portfolio Diversification Drives Guidance Hike
  October 30, 2024
• Bausch Health (BHC) Q2 2024: Solta Asia Revenue Doubles, Diversification Urgency Rises
  August 01, 2024
• Bausch Health (BHC) Q1 2024: Solta Surges 23% Organically, Pipeline Execution Anchors Growth Narrative
  May 02, 2024
• Bausch Health (BHC) Q4 2023: Debt Down $670M as R&D and International Units Drive Strategic Reset
  February 22, 2024

Browse all companies